DXR Daxor Corporation - Closed End Fund
NASDAQ · Health Care · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Mar 28, 2012
$10.62
· of 52w range
· above low
· to high
$8.5652w low
$14.7652w high
Market Cap (MRQ)
$45M
your badges
52W Range
$9–$15
Analyst Rating
BUY
Price Target
$20
P/E
·
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
DXR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$10.62
Market Cap (MRQ)
$45M
52W Range
$9–$15
DXR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Revenue·2010-12-31 → 2011-12-31
Free Cash Flow·2011-12-31 → 2011-12-31
Net margin·2011-12-31 → 2011-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | DXR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 1.2 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | DXR | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 1.7 | · | · | · | |
| Quick Ratio (MRQ) | 1.1 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Annualized Payout≈$0.03
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Jan 5, 2018 | $0.03 | USD | ≈0.72% |
| Dec 20, 2016 | $0.03 | USD | ≈0.35% |
| Dec 18, 2015 | $0.04 | USD | ≈0.51% |
| Dec 4, 2014 | $0.03 | USD | ≈0.47% |
| Dec 5, 2013 | $0.05 | USD | ≈0.71% |
| Dec 7, 2012 | $0.10 | USD | ≈2.6% |
| Aug 10, 2012 | $0.10 | USD | ≈1.1% |
| Nov 16, 2011 | $0.10 | USD | ≈9.3% |
| May 27, 2011 | $0.15 | USD | ≈9.5% |
| Dec 14, 2010 | $0.65 | USD | ≈9.8% |
| Sep 13, 2010 | $0.25 | USD | ≈13.6% |
| May 27, 2010 | $0.10 | USD | ≈12.5% |
| Dec 8, 2009 | $1.00 | USD | ≈17.4% |
| Aug 21, 2009 | $0.25 | USD | ≈12.3% |
| May 27, 2009 | $0.10 | USD | ≈15.9% |
| Dec 10, 2008 | $1.00 | USD | ≈9.7% |
| Oct 31, 2008 | $0.25 | USD | ≈3.2% |
| Jul 24, 2008 | $0.25 | USD | ≈1.4% |
| Apr 28, 1998 | $0.13 | USD | ≈0.89% |
| Apr 28, 1997 | $0.50 | USD | ≈6.0% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
1570.5%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Sept. 30, 2007 | $0.43 | $0.10 | 325.7% | |
| June 30, 2007 | $0.51 | $0.01 | 4949.5% | |
| March 31, 2007 | $0.66 | $-0.03 | 2278.2% | |
| Dec. 31, 2006 | $0.01 | $-0.02 | 149.5% | |
| March 31, 2006 | $0.01 | $-0.02 | 149.5% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Revenue | $1M | $2M | |
| Cost of Revenue | $652.5K | $727.6K | |
| Gross Profit | $793.8K | $851.6K | |
| R&D Expense | $3M | $3M | |
| SG&A Expense | $4M | $3M | |
| Operating Expenses | $7M | $7M | |
| Operating Income | $-6M | $-6M | |
| Other Non-op | $-168.9K | $-61.7K | |
| Income Tax | $-5M | $3M | |
| Net Income | $-7M | $5M | |
| EBITDA | $-6M | · |
Balance Sheet
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Cash & Equivalents | $59.6K | $57.7K | |
| Short-term Investments | $56M | $54M | |
| Receivables | $219.7K | $178.8K | |
| Inventory | $301.5K | $363.6K | |
| Prepaid Expense | $209.3K | $130.6K | |
| Current Assets | $82M | $87M | |
| PP&E (Net) | $4M | $4M | |
| Other Non-current Assets | $37.2K | $37.2K | |
| Total Assets | $86M | $91M | |
| Accounts Payable | $525.2K | $436.5K | |
| Current Liabilities | $49M | $44M | |
| Total Liabilities | $50M | $44M | |
| Common Stock | $53.2K | $53.2K | |
| Paid-in Capital | $11M | $11M | |
| Retained Earnings | $25M | $33M | |
| Treasury Stock | $12M | $12M | |
| AOCI | $13M | $15M | |
| Stockholders' Equity | $36M | $47M | |
| Liabilities + Equity | $86M | $91M | |
| Shares Outstanding | 4,202,351 | 4,226,137 |
Cash Flow
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Stock-based Comp | $9.7K | · | |
| Deferred Tax | $1M | $606.4K | |
| Operating Cash Flow | $-7M | $-6M | |
| CapEx | $123.2K | $324.7K | |
| Investing Cash Flow | $-11M | $9M | |
| Dividends Paid | $1M | $4M | |
| Financing Cash Flow | $18M | $-4M | |
| Net Change in Cash | $1.9K | $-219.3K | |
| Taxes Paid | $3M | $2M | |
| Free Cash Flow | $-7M | · |
Profitability
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Gross Margin | 54.9% | · | |
| Operating Margin | -400.1% | · | |
| Net Margin | -496.8% | · | |
| EBITDA Margin | -400.1% | · | |
| ROA | -8.1% | · | |
| ROE | -17.3% | · |
Liquidity & Solvency
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Current Ratio | 1.7 | · | |
| Quick Ratio | 1.1 | · |
Efficiency
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Asset Turnover | 0.0 | · | |
| Inventory Turnover | 2.0 | · | |
| Receivables Turnover | 7.3 | · |
Per Share
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Book Value / Share | $8.62 | · | |
| Cash / Share | $0.01 | · | |
| Dividend Paid / Share | $0.25 | $1.00 |
Valuation (TTM)
| Metric | Trend | 2011 | 2010 |
|---|---|---|---|
| Revenue TTM | $1M | $2M | |
| Net Income TTM | $-7M | $5M | |
| Market Cap | $38M | · | |
| P/S | 26.4 | · | |
| P/B | 1.1 | · | |
| P / Cash Flow | -5.9 | · | |
| P / FCF | -5.8 | · | |
| Dividend Yield | 2.8% | · | |
| Payout Ratio | -14.7% | · | |
| Annual Payout | $1M | $4M |
Income Statement
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Revenue | $369.8K | $340.9K | $358.1K | $361.4K | |
| Cost of Revenue | $177.0K | $149.4K | $160.7K | $184.7K | |
| Gross Profit | $192.9K | $191.5K | $197.4K | $176.7K | |
| R&D Expense | $709.5K | $637.1K | $669.8K | $720.4K | |
| SG&A Expense | $489.0K | $815.6K | $871.4K | $983.3K | |
| Operating Expenses | $1M | $1M | $2M | $2M | |
| Operating Income | $-1M | $-1M | $-1M | $-2M | |
| Interest Expense | · | $29.8K | $81.3K | · | |
| Other Non-op | $5M | $-6M | $976.9K | $-9M | |
| Income Tax | $-1M | $-3M | $-182.3K | $1M | |
| Net Income | $-1M | $-4M | $-184.5K | $2M | |
| Shares (Basic) | · | 4,219,026 | 4,225,349 | · | |
| EBITDA | · | $-1M | $-1M | · |
Balance Sheet
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Cash & Equivalents | $59.6K | $29.7K | $111.8K | $57.7K | |
| Short-term Investments | $56M | $52M | $54M | $54M | |
| Receivables | $219.7K | $189.6K | $193.5K | $178.8K | |
| Inventory | $301.5K | $313.5K | $357.3K | $363.6K | |
| Prepaid Expense | $209.3K | $338.3K | $184.3K | $130.6K | |
| Current Assets | $82M | $84M | $92M | $87M | |
| PP&E (Net) | $4M | $4M | $4M | $4M | |
| Other Non-current Assets | $37.2K | $37.2K | $37.2K | $37.2K | |
| Total Assets | $86M | $88M | $96M | $91M | |
| Accounts Payable | $525.2K | $971.1K | $1M | $436.5K | |
| Current Liabilities | $49M | $50M | $50M | $44M | |
| Total Liabilities | $50M | $51M | $51M | $44M | |
| Common Stock | $53.2K | $53.2K | $53.2K | $53.2K | |
| Paid-in Capital | $11M | $11M | $11M | $11M | |
| Retained Earnings | $25M | $27M | $31M | $33M | |
| Treasury Stock | $12M | $12M | $12M | $12M | |
| AOCI | $13M | $12M | $16M | $15M | |
| Stockholders' Equity | $36M | $38M | $46M | $47M | |
| Liabilities + Equity | $86M | $88M | $96M | $91M | |
| Shares Outstanding | 4,202,351 | 4,216,643 | 4,223,793 | 4,226,137 |
Cash Flow
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Stock-based Comp | $3.9K | $3.9K | · | · | |
| Operating Cash Flow | $-989.9K | $-613.2K | · | $-2M | |
| CapEx | $4.7K | $58.2K | · | $35.0K | |
| Investing Cash Flow | $-8M | $-3M | · | $6M | |
| Stock Repurchased | · | $107 | · | · | |
| Dividends Paid | $420.5K | $0 | · | $3M | |
| Financing Cash Flow | $9M | $4M | · | $-5M | |
| Net Change in Cash | $29.9K | $-82.1K | · | $-49.3K | |
| Taxes Paid | $5.5K | $10.5K | · | $868.3K |
Profitability
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Gross Margin | · | 56.2% | 55.1% | · | |
| Operating Margin | · | -369.9% | -375.2% | · | |
| Net Margin | · | -1227.2% | -51.5% | · | |
| EBITDA Margin | · | -369.9% | -375.2% | · | |
| ROA | · | -9.5% | -0.38% | · | |
| ROE | · | -22.2% | -0.81% | · |
Liquidity & Solvency
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Current Ratio | · | 1.7 | 1.8 | · | |
| Quick Ratio | · | 1.0 | 1.1 | · | |
| Interest Coverage | · | -42.4 | -16.5 | · |
Efficiency
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | · | |
| Inventory Turnover | · | 1.0 | 0.9 | · | |
| Receivables Turnover | · | 3.6 | 3.7 | · |
Per Share
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Book Value / Share | · | $8.92 | $10.79 | · | |
| Cash / Share | · | $0.01 | $0.03 | · | |
| Dividend Paid / Share | $0.10 | $0.00 | $0.15 | $0.65 |
Valuation (TTM)
| Metric | Trend | Q4 2011 | Q3 2011 | Q2 2011 | Q4 2010 |
|---|---|---|---|---|---|
| Market Cap | · | $45M | $43M | · | |
| P/B | · | 1.2 | 0.9 | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2011-12-31 | 2010-12-31 |
|---|---|---|
| Revenue | $1M | $2M |
| Gross Margin % | 54.9% | · |
| Operating Margin % | -400.1% | · |
| Net Income | $-7M | $5M |
| Metric | 2011-12-31 | 2010-12-31 |
|---|---|---|
| Current Ratio | 1.7 | · |
| Quick Ratio | 1.1 | · |
| Metric | 2011-12-31 | 2010-12-31 |
|---|---|---|
| Free Cash Flow | $-7M | · |
Institutional owners (13F) 16 filers · $2.6M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
16
Value held
$2.6M
New positions
1
Exited positions
1
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 1 (-7 vs prior Q) | 1 (0 vs prior Q) | 8 (+8 vs prior Q) | 1 (-2 vs prior Q) | +2K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $723,163 | 49,028 | 28.14% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $495,635 | 48,831 | 19.29% | Shares |
| Aristides Capital LLC | $429,180 | 41,689 | 16.70% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $302,883 | 29,421 | 11.79% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $275,380 | 27,131 | 10.72% | Shares |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $128,685 | 12,500 | 5.01% | Shares |
| Crescent Grove Advisors, LLC | $127,892 | 12,423 | 4.98% | Shares |
| SBI Securities Co., Ltd. | $32,233 | 3,131 | 1.25% | Shares |
| MORGAN STANLEY | $31,780 | 3,087 | 1.24% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $10,526 | 1,037 | 0.41% | Shares |
| OSAIC HOLDINGS, INC. | $5,145 | 500 | 0.20% | Shares |
| Tower Research Capital LLC (TRC) | $3,140 | 305 | 0.12% | Shares |
| THOMPSON SIEGEL & WALMSLEY LLC | $2,489 | 241,767 | 0.10% | Shares |
| UBS Group AG | $1,771 | 172 | 0.07% | Shares |
| JPMORGAN CHASE & CO | $61 | 6 | 0.00% | Shares |
| WELLS FARGO & COMPANY/MN | $2 | 0 | 0.00% | Shares |
Company insiders 22 insiders · 8 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Richard Feldschuh | Chief Executive Officer | June 23, 2026 A | 243,694 | 1 | 0 | $9,070 |
| Robert J Michel | Chief Financial Officer | June 23, 2026 A | 33,050 | 1 | 0 | $9,900 |
| Gary Joseph Fischman | President | Dec. 1, 2004 X | · | 0 | 0 | $0 |
| John Jefferies | Chief Medical Officer | Aug. 28, 2026 A | 26,008 | 0 | 0 | $0 |
| Jonathan Adam Feldschuh | Chief Scientific Officer | June 23, 2026 A | 78,908 | 0 | 0 | $0 |
| Soren Thompson | VP, Business Development | July 31, 2018 P | 1,950 | 0 | 0 | $0 |
| Diane Marie Meegan | Corporate Secretary | April 10, 2015 S | 500 | 0 | 0 | $0 |
| Everis Engstrom | Vice President | Dec. 4, 2008 P | 500 | 0 | 0 | $0 |
| Caleb Desrosiers | Director | June 23, 2026 A | 3,157 | 0 | 0 | $0 |
| Joy S. Goudie | Director | June 23, 2026 A | 300 | 0 | 0 | $0 |
| Henry D. Cremisi | Director | June 23, 2026 A | · | 0 | 0 | $0 |
| Edward Feuer | Director | June 23, 2026 A | 1,000 | 0 | 0 | $0 |
| James A Lombard | Director | July 11, 2023 A | 1,500 | 0 | 0 | $0 |
| Bernhard Saxe | Director | June 25, 2020 A | 200 | 0 | 0 | $0 |
| Martin S Wolpoff | Director | June 25, 2020 A | 4,000 | 0 | 0 | $0 |
| Robert Willens | Director | May 9, 2013 P | 18,164 | 0 | 0 | $0 |
| Philip Nordan Hudson | Director | March 28, 2012 P | 146,200 | 0 | 0 | $0 |
| Robert G Moussa | Director | Oct. 31, 2006 P | 1,000 | 0 | 0 | $0 |
| Stephen Valentine | Director | Oct. 13, 2005 P | 500 | 0 | 0 | $0 |
| Estate of Joseph Feldschuh | 10% owner | Sept. 18, 2023 G | 2,549,455 | 0 | 0 | $0 |
| Joseph Feldschuh | 10% owner | March 9, 2018 S | 2,774,455 | 0 | 0 | $0 |
| Bruce Slovin | · | May 26, 2004 S | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 1 ETF
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VTI · VANGUARD INDEX FUNDS | 0.00% | 48,831 SH | Aug. 19, 2026 | Daily |
DXR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 6 analysts
BUY
Median target
$20.00
+88.3%
1 16.7%
Strong Buy
4 66.7%
Buy
1 16.7%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
2 analysts · 2026-09-29Mean target $20.00 +88.3%
← Below all targets
Current price $10.62
Low$18.00
Mean$20.00
High$22.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-K filed Mar 28, 2012